Literature DB >> 30926234

Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States.

Spencer C Wei1, Roshan Sharma2, Nana-Ama A S Anang1, Jacob H Levine3, Yang Zhao4, James J Mancuso1, Manu Setty3, Padmanee Sharma5, Jing Wang4, Dana Pe'er6, James P Allison7.   

Abstract

Co-stimulation regulates T cell activation, but it remains unclear whether co-stimulatory pathways also control T cell differentiation. We used mass cytometry to profile T cells generated in the genetic absence of the negative co-stimulatory molecules CTLA-4 and PD-1. Our data indicate that negative co-stimulation constrains the possible cell states that peripheral T cells can acquire. CTLA-4 imposes major boundaries on CD4+ T cell phenotypes, whereas PD-1 subtly limits CD8+ T cell phenotypes. By computationally reconstructing T cell differentiation paths, we identified protein expression changes that underlied the abnormal phenotypic expansion and pinpointed when lineage choice events occurred during differentiation. Similar alterations in T cell phenotypes were observed after anti-CTLA-4 and anti-PD-1 antibody blockade. These findings implicate negative co-stimulation as a key regulator and determinant of T cell differentiation and suggest that checkpoint blockade might work in part by altering the limits of T cell phenotypes.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30926234      PMCID: PMC6664799          DOI: 10.1016/j.immuni.2019.03.004

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  77 in total

1.  Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength.

Authors:  Jackson G Egen; James P Allison
Journal:  Immunity       Date:  2002-01       Impact factor: 31.745

2.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones.

Authors:  F A Harding; J G McArthur; J A Gross; D H Raulet; J P Allison
Journal:  Nature       Date:  1992-04-16       Impact factor: 49.962

3.  B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse.

Authors:  Tsvetelina Pentcheva-Hoang; Jackson G Egen; Kathleen Wojnoonski; James P Allison
Journal:  Immunity       Date:  2004-09       Impact factor: 31.745

4.  Reversal of the TCR stop signal by CTLA-4.

Authors:  Helga Schneider; Jos Downey; Andrew Smith; Bernd H Zinselmeyer; Catherine Rush; James M Brewer; Bin Wei; Nancy Hogg; Paul Garside; Christopher E Rudd
Journal:  Science       Date:  2006-08-24       Impact factor: 47.728

5.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

6.  Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells.

Authors:  Bertram Bengsch; Takuya Ohtani; Omar Khan; Manu Setty; Sasikanth Manne; Shaun O'Brien; Pier Federico Gherardini; Ramin Sedaghat Herati; Alexander C Huang; Kyong-Mi Chang; Evan W Newell; Niels Bovenschen; Dana Pe'er; Steven M Albelda; E John Wherry
Journal:  Immunity       Date:  2018-05-15       Impact factor: 31.745

7.  PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues.

Authors:  Mary E Keir; Gordon J Freeman; Arlene H Sharpe
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

8.  Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.

Authors:  Clélia Coutzac; Julien Adam; Emilie Soularue; Michael Collins; Antoine Racine; Charlotte Mussini; Lisa Boselli; Nyam Kamsukom; Christine Mateus; Mélinda Charrier; Lydie Cassard; David Planchard; Vincent Ribrag; Karim Fizazi; Yohann Loriot; Patricia Lepage; Jean-Yves Scoazec; Caroline Robert; Franck Carbonnel; Nathalie Chaput
Journal:  J Crohns Colitis       Date:  2017-10-01       Impact factor: 9.071

9.  A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells.

Authors:  Tie Zheng Hou; Omar S Qureshi; Chun Jing Wang; Jennifer Baker; Stephen P Young; Lucy S K Walker; David M Sansom
Journal:  J Immunol       Date:  2015-01-28       Impact factor: 5.422

10.  The geometry of the Pareto front in biological phenotype space.

Authors:  Hila Sheftel; Oren Shoval; Avi Mayo; Uri Alon
Journal:  Ecol Evol       Date:  2013-04-17       Impact factor: 2.912

View more
  35 in total

Review 1.  mTOR and other effector kinase signals that impact T cell function and activity.

Authors:  Darienne R Myers; Benjamin Wheeler; Jeroen P Roose
Journal:  Immunol Rev       Date:  2019-09       Impact factor: 12.988

Review 2.  CD8+ T cell states in human cancer: insights from single-cell analysis.

Authors:  Anne M van der Leun; Daniela S Thommen; Ton N Schumacher
Journal:  Nat Rev Cancer       Date:  2020-02-05       Impact factor: 60.716

Review 3.  Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.

Authors:  Kristian M Hargadon
Journal:  Clin Transl Med       Date:  2020-01

Review 4.  T cell costimulation, checkpoint inhibitors and anti-tumor therapy.

Authors:  Dipankar Nandi; Sanmoy Pathak; Taru Verma; Madhulika Singh; Avik Chattopadhyay; Samriddhi Thakur; Abinaya Raghavan; Abhijeet Gokhroo
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

5.  Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability.

Authors:  Sonia Guedan; Aviv Madar; Victoria Casado-Medrano; Carolyn Shaw; Anna Wing; Fang Liu; Regina M Young; Carl H June; Avery D Posey
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 6.  Tumour heterogeneity and the evolutionary trade-offs of cancer.

Authors:  Jean Hausser; Uri Alon
Journal:  Nat Rev Cancer       Date:  2020-02-24       Impact factor: 60.716

Review 7.  Time to dissect the autoimmune etiology of cancer antibody immunotherapy.

Authors:  Michael Dougan; Massimo Pietropaolo
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

8.  NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma.

Authors:  Vilde Drageset Haakensen; Anna K Nowak; Espen Basmo Ellingsen; Saima Jamil Farooqi; Maria Moksnes Bjaanæs; Henrik Horndalsveen; Tine Mcculloch; Oscar Grundberg; Susana M Cedres; Åslaug Helland
Journal:  J Transl Med       Date:  2021-05-31       Impact factor: 5.531

9.  Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child.

Authors:  Silvia Vilarinho; Richard P Lifton; Bertrand Boisson; Laurent Abel; Dusan Bogunovic; Nico Marr; Luigi D Notarangelo; Stuart G Tangye; Tasuku Honjo; Philippe Gros; Stéphanie Boisson-Dupuis; Jean-Laurent Casanova; Masato Ogishi; Rui Yang; Caner Aytekin; David Langlais; Mathieu Bourgey; Taushif Khan; Fatima Al Ali; Mahbuba Rahman; Ottavia M Delmonte; Maya Chrabieh; Peng Zhang; Conor Gruber; Simon J Pelham; András N Spaan; Jérémie Rosain; Wei-Te Lei; Scott Drutman; Matthew D Hellmann; Margaret K Callahan; Matthew Adamow; Phillip Wong; Jedd D Wolchok; Geetha Rao; Cindy S Ma; Yuka Nakajima; Tomonori Yaguchi; Kenji Chamoto; Samuel C Williams; Jean-Francois Emile; Flore Rozenberg; Michael S Glickman; Franck Rapaport; Gaspard Kerner; Garrett Allington; Ilhan Tezcan; Deniz Cagdas; Ferda O Hosnut; Figen Dogu; Aydan Ikinciogullari; V Koneti Rao; Leena Kainulainen; Vivien Béziat; Jacinta Bustamante
Journal:  Nat Med       Date:  2021-06-28       Impact factor: 53.440

10.  Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis.

Authors:  Sara Bjursten; Ankur Pandita; Zhiyuan Zhao; Charlotta Fröjd; Lars Ny; Christer Jensen; Tobias Ullerstam; Henrik Jespersen; Jan Borén; Malin Levin; Henrik Zetterberg; Anna Rudin; Max Levin
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.